ClinicalTrials.gg
RecruitingNCT06481020Updated Jul 1, 2024

Plant Sterols on Cardiovascular Markers, Microbiota and Sterol Metabolism (Cardiofoodsterol)

An interventional study of Plant sterols 2g/day and Placebo in Cardiovascular Diseases, Hypercholesterolemia and Prediabetic State, sponsored by University of Valencia. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-07-01.

Sponsored by University of Valencia · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Potential cholesterol-lowering effect of a regular intake of a plant sterol (PS)-containing food supplement, in overweight/obese type 1 or 2, normoglycemic/pre-diabetic, with LDL-cholesterol values > 115 mg/dl and not pharmacologically treated participants treated with the PS-containing food supplement or placebo supplement.

Read the detailed description

Cardiovascular disease (CVD) is the leading cause of death worldwide, with hypercholesterolemia being one of the main risk factors for CVD. The deposition and oxidation of LDL-cholesterol particles triggers a series of molecular events favoring chronic low-grade inflammation, endothelial dysfunction and oxidative stress. This situation promotes atherogenesis thus increasing cardiovascular risk. Obesity favors the secretion of pro-inflammatory mediators and promotes the recruitment of macrophages to adipose tissue, insulin resistance, hyperglycemia and hyperlipidemia, thus increasing the risk of CVD. In addition, obesity has been associated with gut dysbiosis, which in turn is associated with atherosclerosis in some studies. Beneficial effects of PS on LDL-cholesterol and inflammatory, endothelial dysfunction and oxidative stress markers have been reported by several clinical trials. A meta-analysis suggests a lowering effect of PS on body mass index (BMI) in participants with BMI>25. Furthermore, the consumption of PS has been beneficially associated in in vitro studies with changes in intestinal microbial profile, sterol metabolism and short chain fatty acids (SCFA) production. Therefore, the hypothesis is if the consumption of PS as a food supplementation could reduce cardiovascular risk. The present study aims to evaluate the LDL-cholesterol serum levels after regular intake of a food supplement containing PS (2 g/day) in overweight/obese type 1 or 2 patients, normoglycemic /pre-diabetic and with LDL-cholesterol values > 115 mg/dl not pharmacologically treated. This is a crossover study with 21 participants (intake of a food supplement containing PS) and 21 participants (intake of excipient-based placebo), with a first intervention period of 8 weeks. After a 6-week washout period, the treatments are switched, with a second intervention period of 8 weeks. In addition, to the LDL-cholesterol lowering assessment, other biochemical, hematological, inflammatory, endothelial dysfunction and oxidative stress parameters are assessed in serum samples. Moreover, sterol and metabolite profiling in serum and feces, microbiota modulation, anthropometric measurements and body composition, bioimpedance, dietary intake and physical activity questionnaire are evaluated. All parameters are evaluated at the beginning (weeks 0 and 14) and at the end of each intervention period (weeks 8 and 22).

02

Conditions studied

  • Cardiovascular Diseases
  • Hypercholesterolemia
  • Prediabetic State
  • Overweight and Obesity

Keywords

  • Cholesterol LDL
  • Plant Sterols
  • Inflammation
  • Oxidative Stress
  • Microbiota
  • Sterol Metabolites
  • Endothelial function
  • Bioimpedance
  • Dietary Intake
  • Physical Activity
03

In context

Cardiovascular Diseases

5,376 studies on the registry are indexed under Cardiovascular Diseases; 940 are open to participants now.

This study's planned enrollment of 42 is below the median of 100 across 3,086 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

University of Valencia is the lead sponsor of 357 studies on the registry; 75 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • : 27-29.9 or 30-39.9
  • Plasmatic glucose: \< 100mg/dl or 100-125mg/dl
  • Glycosylated : \< 5.7 or 5.7-6.4
  • LDL cholesterol > 115mg/dL
  • Serum levels of biochemical and hematological parameters and fat-soluble vitamins within reference ranges.

Exclusion criteria

Exclusion Criteria:

  • Subjects on cholesterol-lowering pharmacological treatment
  • Smokers
  • Alcohol consumption above 30 g/day
  • Pregnant or lactating women
  • Any infection, serious illness or co-morbidity that may affect the bioavailability of PS (e.g., malabsorption, celiac disease, allergies or food intolerances)
  • Diseases of the gastrointestinal tract
  • Antibiotic, hormonal or anabolic treatment
  • Participants consuming foods enriched with PS or food supplements that contain PS
  • Participants who follow specialist weight loss diets, vegans or vegetarians
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    Dietary Supplement

    PS-containing dietary supplement Sachet containing a powdered microencapsulated free plant sterols (2 g ingredient/day)

    Dietary Supplement: Plant sterols 2g/day

  • Placebo comparator
    Placebo

    Sachet containing the powdered excipients of the dietary supplement

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementPlant sterols 2g/day

    Drug page: PhytosterolsStudies of PhytosterolsPhytosterols pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    PS-containing dietary supplement Sachet containing a powdered microencapsulated free plant sterols (2 g ingredient/day) during 8 weeks

  • Dietary supplementPlacebo

    Sachet containing the powdered excipients of the dietary supplement during 8 weeks

06

What researchers measure

Primary outcomes

  1. Changes in plasmatic LDL-c

    LDL-c, calculated by the Friedewald's formula, with repeated measures (at the beginning and at the end of each period the intervention)

    Time frame: 0, 8, 14 and 22 weeks

Secondary outcomes

  1. Changes in plasmatic total cholesterol

    Total cholesterol, assessed by enzymatic-colorimetric methods, with repeated measures (at the beginning and at the end of each period the intervention)

    Time frame: 0, 8, 14 and 22 weeks

  2. Changes in plasmatic HDL-c

    HDL-c, assessed by enzymatic-colorimetric methods, with repeated measures (at the beginning and at the end of each period the intervention)

    Time frame: 0, 8, 14 and 22 weeks

  3. Changes in plasmatic non-HDL cholesterol

    Non-HDL cholesterol, calculated by subtracting HDL-c from total cholesterol, with repeated measures (at the beginning and at the end of each period the intervention)

    Time frame: 0, 8, 14 and 22 weeks

  4. Changes in plasmatic triglycerides

    Triglycerides, assessed by enzymatic-colorimetric methods, with repeated measures (at the beginning and at the end of each period the intervention)

    Time frame: 0, 8, 14 and 22 weeks

  5. Changes in plasmatic Apo A

    Apo A, assessed by enzymatic-colorimetric methods, with repeated measures (at the beginning and at the end of each period the intervention)

    Time frame: 0, 8, 14 and 22 weeks

  6. Changes in plasmatic Apo B

    Apo B, assessed by enzymatic-colorimetric methods, with repeated measures (at the beginning and at the end of each period the intervention

    Time frame: 0, 8, 14 and 22 weeks

  7. Changes in plasmatic fibrinogen

    Fibrinogen, assessed by Clauss coagulometric method, with repeated measures (at the beginning and at the end of each period the intervention)

    Time frame: 0, 8, 14 and 22 weeks

  8. Changes in plasmatic High-sensitivity C-reactive protein (hsCRP)

    hs CRP, assessed by enzymatic-colorimetric methods, with repeated measures (at the beginning and at the end of each period the intervention)

    Time frame: 0, 8, 14 and 22 weeks

  9. Changes in plasmatic glucose

    Glucose, assessed by enzymatic-colorimetric methods, with repeated measures (at the beginning and at the end of each period the intervention)

    Time frame: 0, 8, 14 and 22 weeks

  10. Changes in plasmatic insulin

    Insulin, assessed by enzymatic-colorimetric methods, with repeated measures (at the beginning and at the end of each period the intervention

    Time frame: 0, 8, 14 and 22 weeks

  11. Changes in plasmatic Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)

    HOMA-IR, calculated by mathematical formula from the fasting insulin and fasting glucose levels, with repeated measures (at the beginning and at the end of each period the intervention)

    Time frame: 0, 8, 14 and 22 weeks

  12. Changes in serum levels of the sterols and metabolites profile

    Profile sterols and metabolites, assessed by gas chromatography coupled with flame ionization detector (GC-FID), with repeated measures (at the beginning and at the end of each period the intervention)

    Time frame: 0, 8, 14 and 22 weeks

  13. Changes in feces levels of the sterols and metabolites profile

    Profile sterols and metabolites, assessed by gas chromatography coupled with flame ionization detector (GC-FID), with repeated measures (at the beginning and the end of each period the intervention)

    Time frame: 0, 8, 14 and 22 weeks

  14. Changes in serum interleukin 10 (IL-10)

    IL-10, assessed by immunochemical techniques, with repeated measures (at the beginning and the end of each period the intervention)

    Time frame: 0, 8, 14 and 22 weeks

  15. Changes in serum interleukin 12p70 (IL-12p70)

    IL-12p70, assessed by immunochemical techniques, with repeated measures (at the beginning and the end of each period the intervention)

    Time frame: 0, 8, 14 and 22 weeks

  16. Changes in serum interleukin 1β (IL-1β)

    IL-1β, assessed by immunochemical techniques, with repeated measures (at the beginning and the end of each period the intervention)

    Time frame: 0, 8, 14 and 22 weeks

  17. Changes in serum interleukin 6 (IL-6)

    IL-6, assessed by immunochemical techniques, with repeated measures (at the beginning and the end of each period the intervention)

    Time frame: 0, 8, 14 and 22 weeks

  18. Changes in serum interleukin 8 (IL-8)

    IL-8, assessed by immunochemical techniques, with repeated measures (at the beginning and the end of each period the intervention)

    Time frame: 0, 8, 14 and 22 weeks

  19. Changes in serum tumor necrosis factor alpha (TNFα)

    TNFα, assessed by immunochemical techniques, with repeated measures (at the beginning and the end of each period the intervention)

    Time frame: 0, 8, 14 and 22 weeks

  20. Changes in serum vascular cell adhesion molecule-1 (VCAM-1)

    VCAM-1, assessed by immunochemical techniques, with repeated measures (at the beginning and the end of each period the intervention)

    Time frame: 0, 8, 14 and 22 weeks

  21. Changes in serum E-Selectin

    E- Selectin, assessed by immunochemical techniques, with repeated measures (at the beginning and the end of each period the intervention)

    Time frame: 0, 8, 14 and 22 weeks

  22. Changes in serum endothelin (ET-1)

    ET-1, assessed by immunochemical techniques, with repeated measures (at the beginning and the end of each period the intervention

    Time frame: 0, 8, 14 and 22 weeks

  23. Changes in serum plasminogen activator inhibitor-1(PAI-1)

    PAI-1, assessed by immunochemical techniques, with repeated measures (at the beginning and the end of each period the intervention)

    Time frame: 0, 8, 14 and 22 weeks

  24. Changes in plasmatic LDL-cholesterol oxidation

    LDL-cholesterol oxidation, assessed by enzyme kits, with repeated measures (at the beginning and the end of each period the intervention)

    Time frame: 0, 8, 14 and 22 weeks

  25. Changes in plasmatic 8-isoprostane

    8-isoprostane, assessed by enzyme kits, with repeated measures (at the beginning and the end of each period the intervention)

    Time frame: 0, 8, 14 and 22 weeks

  26. Changes in plasmatic malondialdehyde (MDA)

    MDA, assessed by ultra-performance liquid chromatography-MS (UPLC-MS), with repeated measures (at the beginning and the end of each period the intervention

    Time frame: 0, 8, 14 and 22 weeks

  27. Changes in reduced glutathiones (GSH)

    GSH, assessed by ultra-performance liquid chromatography-MS (UPLC-MS), with repeated measures (at the beginning and the end of each period the intervention)

    Time frame: 0, 8, 14 and 22 weeks

  28. Changes in oxidized glutathione (GSSG)

    GSSG, assessed by ultra-performance liquid chromatography-MS (UPLC-MS), with repeated measures (at the beginning and the end of each period the intervention)

    Time frame: 0, 8, 14 and 22 weeks

  29. Changes in the composition of microbiota in feces

    Composition of microbiota, assessed by genetic sequencing and subsequent biostatistical analysis, with repeated measures (at the beginning and the end of each period the intervention)

    Time frame: 0, 8, 14 and 22 weeks

  30. Changes in feces of short-chain fatty acids (SCFAs)

    SCFAs, assessed by high-performance liquid chromatography with an ultraviolet detector (HPCL-UV), with repeated measures (at the beginning and the end of each period the intervention)

    Time frame: 0, 8, 14 and 22 weeks

  31. Changes in plasmatic levels of cholesterol oxidation products (COPs)

    COPs, assessed by gas chromatography-mass spectrometry, with repeated measures (at the beginning and the end of each period the intervention)

    Time frame: 0, 8, 14 and 22 weeks

  32. Changes in body weight (WT)

    WT, assessed by standard balance scale, with repeated measures (at the beginning and the end of each period the intervention)

    Time frame: 0, 8, 14 and 22 weeks

  33. Changes in body height (HT)

    HT, assessed by tape measure, with repeated measures (at the beginning and the end of each period the intervention)

    Time frame: 0, 8, 14 and 22 weeks

  34. Changes in body circumferences

    Circumferences, assessed by tape measure, with repeated measures (at the beginning and the end of each period the intervention)

    Time frame: 0, 8, 14 and 22 weeks

  35. Changes in Bioelectrical impedance analysis (BIA)

    BIA, assessed by bio-impedance meter, with repeated measures (at the beginning and the end of each period the intervention)

    Time frame: 0, 8, 14 and 22 weeks

  36. Assessment of dietary intake

    Food frequency survey Questionnaire (FFQ) is used, consisting in 136 questions divided into the different food groups (dairy products; eggs, meat and fish; vegetables; fruit; pulses and cereals; oils and fats; bakery and confectionery; miscellaneous; drinks) indicating the average frequency of consumption during the past year, which can be scored as never or almost never, per month (1-3), per week (1, 2-4,5-6), per day (1, 2-3, 4-6, 6+), with repeated of questionnaire (at the beginning and the end of each period the intervention)

    Time frame: 0, 8, 14 and 22 weeks

  37. Evaluation of the physical activity to measure quality of life

    International physical activity questionnaire-short form (IPAC-SF) is used, consisting in 7 questions. Intensity, frequency and duration of the exercise are evaluated through metabolic equivalent of task (METs). This allows to differentiate 3 levels of physical activity: Low: Not enough activity to achieve the next level Moderate: 3 or more days of vigorous physical activity for at least 20 minutes per day, 5 or more days of moderate physical activity and/or walking at least 30 minutes per day, or 5 or more days of any combination of walking, moderate or vigorous physical activity achieving at least a total of 600 METs. High: Vigorous physical activity at least 3 days per week achieving a total of a least 1500 METs, or 7 days of any combination of walking, with moderate and/or vigorous physical activity, achieving a total of a least 3000 METs. With repeated of questionnaire (at the beginning and the end of each period the intervention)

    Time frame: 0, 8, 14 and 22 weeks

  38. Evaluation of the Mediterranean diet adherence to measure quality of life

    Mediterranean diet adherence screener (MEDAS) is used, consisting in 14 questions (each one 0 or 1 point, final score between 0 and 14). Results are ranged between 0-7 points (low adherence), 7-10 (moderate adherence), and 10-14 (high adherence) With repeated of questionnaire (at the beginning and the end of each period the intervention)

    Time frame: 0, 8, 14 and 22 weeks

07

Study locations

1 of 1 sites recruiting
  • Hospital Universitario y Politécnico La Fe de Valencia
    Valencia, 46026, Spain
    Recruiting
    • Juan Francisco Merino Torres · Contact
08

References and documents

Publications

  • Blanco-Morales V, Garcia-Llatas G, Yebra MJ, Sentandreu V, Lagarda MJ, Alegria A. Impact of a Plant Sterol- and Galactooligosaccharide-Enriched Beverage on Colonic Metabolism and Gut Microbiota Composition Using an In Vitro Dynamic Model. J Agric Food Chem. 2020 Feb 19;68(7):1884-1895. doi: 10.1021/acs.jafc.9b04796. Epub 2019 Sep 26. PubMed 31523960 ↗
  • Blanco-Morales V, Silvestre RLA, Hernandez-Alvarez E, Donoso-Navarro E, Alegria A, Garcia-Llatas G. Influence of Galactooligosaccharides on the Positive Effect of Plant Sterol-Enriched Beverages on Cardiovascular Risk and Sterol Colon Metabolism. J Agric Food Chem. 2022 Jan 19;70(2):532-542. doi: 10.1021/acs.jafc.1c06120. Epub 2022 Jan 11. PubMed 35012310 ↗
  • Caudet J, Trelis M, Cifre S, Tapia G, Soriano JM, Rodrigo R, Merino-Torres JF. Do Intestinal Unicellular Parasites Have a Role in the Inflammatory and Redox Status among the Severely Obese? Antioxidants (Basel). 2022 Oct 23;11(11):2090. doi: 10.3390/antiox11112090. PubMed 36358463 ↗
  • Heggen E, Kirkhus B, Pedersen JI, Tonstad S. Effects of margarine enriched with plant sterol esters from rapeseed and tall oils on markers of endothelial function, inflammation and hemostasis. Scand J Clin Lab Invest. 2015 Apr;75(2):189-92. doi: 10.3109/00365513.2014.992040. Epub 2015 Jan 1. PubMed 25553599 ↗
  • Oliveira Godoy Ilha A, Sutti Nunes V, Silva Afonso M, Regina Nakandakare E, da Silva Ferreira G, de Paula Assis Bombo R, Rodrigues Giorgi R, Marcondes Machado R, Carlos Rocha Quintao E, Lottenberg AM. Phytosterols Supplementation Reduces Endothelin-1 Plasma Concentration in Moderately Hypercholesterolemic Individuals Independently of Their Cholesterol-Lowering Properties. Nutrients. 2020 May 22;12(5):1507. doi: 10.3390/nu12051507. PubMed 32455866 ↗
  • Mannarino E, Pirro M, Cortese C, Lupattelli G, Siepi D, Mezzetti A, Bertolini S, Parillo M, Fellin R, Pujia A, Averna M, Nicolle C, Notarbartolo A. Effects of a phytosterol-enriched dairy product on lipids, sterols and 8-isoprostane in hypercholesterolemic patients: a multicenter Italian study. Nutr Metab Cardiovasc Dis. 2009 Feb;19(2):84-90. doi: 10.1016/j.numecd.2008.03.012. Epub 2008 Aug 31. PubMed 18762410 ↗
  • Menendez-Carreno M, Steenbergen H, Janssen HG. Development and validation of a comprehensive two-dimensional gas chromatography-mass spectrometry method for the analysis of phytosterol oxidation products in human plasma. Anal Bioanal Chem. 2012 Feb;402(6):2023-32. doi: 10.1007/s00216-011-5432-2. Epub 2011 Oct 5. PubMed 21972006 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Dec 2024, 7 months after the start.

Of 1,081 non-industry interventional studies with no phase under Cardiovascular Diseases, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 7 months is below that.

Counting every sponsor, half of 1,220 studies reached it within 26 months; a quarter within 12 and three quarters within 49.

Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2024
First posted
Jul 1, 2024
StartActual
May 21, 2024
Primary completionEst.
Dec 2024
CompletionEst.
Feb 2025
Last update
Jul 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06481020
Collaborators
Hospital Universitario La Fe, University of Bologna
Responsible party
Guadalupe García Llatas (Principal investigator, University of Valencia) — Principal investigator
First posted
Jul 1, 2024
Start date
May 21, 2024
Primary completion
Dec 2024 (estimated)
Completion
Feb 2025 (estimated)
Last update
Jul 1, 2024

Study contacts

Guadalupe Garcia Llatas, Professor
Contact
guadalupe.garcia@uv.es
+34 963543766
Guadalupe Garcia Llatas, Professor
principal investigator · University of Valencia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Phytosterols

Start the discussion